IBOV 171,031.73 ▲ 1.85% IPSA 11,338.38 ▲ 0.89% IPC MEX 65,729.18 ▲ 2.14% MERVAL 2,913,184 ▲ 1.30% COLCAP 2,459.23 ▲ 0.61% BVL PERÚ 58,698.13 ▲ 2.60% USD/BRL5.14▲ 0.02% USD/MXN16.93▲ 0.10% USD/CLP914.28— 0.00% USD/COP3,043▲ 0.02% USD/PEN3.36▲ 0.04% USD/ARS1,499▼ 0.03% USD/UYU40.20— 0.00% USD/PYG5,996— 0.00% USD/BOB11.43— 0.00% USD/DOP58.61▼ 0.07% USD/CRC450.05— 0.00% USD/GTQ7.62— 0.00% USD/HNL26.81— 0.00% USD/NIO36.62— 0.00% USD/VES782.70▲ 0.48% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD 157.28 — 0.00% USD/TTD6.71— 0.00% EUR/BRL6.00▼ 0.03% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73% IBOV 171,031.73 ▲ 1.85% IPSA 11,338.38 ▲ 0.89% IPC MEX 65,729.18 ▲ 2.14% MERVAL 2,913,184 ▲ 1.30% COLCAP 2,459.23 ▲ 0.61% BVL PERÚ 58,698.13 ▲ 2.60% USD/BRL 5.16 ▲ 0.01% USD/MXN 17.06 ▼ 0.24% USD/CLP 913.98 ▲ 0.04% USD/COP 3,140 ▲ 0.03% USD/PEN 3.36 ▼ 0.66% USD/ARS 1,493 ▲ 0.10% USD/UYU 40.27 ▲ 1.24% USD/PYG 5,939 ▲ 1.68% USD/BOB 11.64 ▼ 0.76% USD/DOP 58.34 ▲ 1.25% USD/CRC 445.92 ▲ 0.89% USD/GTQ 7.62 ▲ 2.21% USD/HNL 26.79 ▲ 1.57% USD/NIO 36.62 ▲ 0.69% USD/VES 762.44 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.28 — 0.00% USD/TTD 6.70 ▲ 0.61% EUR/BRL 5.95 ▲ 1.01% BRENT 88.88 ▼ 0.03% WTI 83.11 ▼ 0.11% IRON ORE 161.91 — — COPPER 6.61 ▲ 0.03% GOLD 4,461 ▲ 1.78% SILVER 65.59 ▲ 1.26% SOY 1,184 ▲ 3.20% CORN 480.50 ▲ 10.02% WHEAT 655.00 ▲ 3.93% COFFEE 317.25 ▼ 5.51% SUGAR 16.43 ▼ 1.79% ORANGE JUICE 138.55 ▼ 0.47% COTTON 85.03 ▲ 2.33% COCOA 5,719 ▲ 3.18% BEEF 223.60 ▼ 3.93% CATTLE 339.10 ▼ 3.16% LITHIUM 75.20 ▲ 1.47% PETR4 41.64 ▼ 0.05% VALE3 72.97 ▲ 0.83% ITUB4 38.60 ▼ 1.03% BBDC4 16.85 ▲ 0.36% ABEV3 14.89 ▼ 0.80% BBAS3 19.37 ▲ 0.47% B3SA3 14.26 ▼ 0.21% WEGE3 47.59 ▲ 0.49% PRIO3 59.14 ▼ 0.19% SUZB3 41.33 ▲ 2.35% RENT3 34.68 ▼ 0.09% AZZA3 15.89 ▼ 2.63% CSAN3 3.22 ▼ 1.83% RAIZ4 0.25 — 0.00% PCAR3 2.75 ▼ 0.36% GMAT3 3.65 ▼ 1.08% PSSA3 48.13 ▼ 0.54% CVCB3 1.33 ▼ 2.92% POSI3 3.36 ▲ 2.44% SLCE3 13.34 ▲ 0.30% NATU3 8.14 ▼ 0.73%
since 2009
Monday, August 24, 2026

Covid-19 Brazil

Covid-19: Study Indicates Cured Patients May Retain Immunity for Six Months

By · November 4, 2020 · 2 min read

Daily Brief

The morning intel from across Latin America. Free.

By subscribing you agree to our privacy policy. We never share your email.

RIO DE JANEIRO, BRAZIL – As some vaccines near the finish line in the race for an immunizer, it is still unclear how long the protection offered could last.

A crucial type of defensive blood cell persists for at least six months in people who have been cured of Covid-19, even for those who had no symptoms. This is indicated by a new study that may lessen the concern over immunity and its implications for a vaccine.

As some vaccines near the finish line in the race for an immunizer, it is still unclear how long the protection offered would last.
As some vaccines near the finish line in the race for an immunizer, it is still unclear how long the protection offered would last. (Photo internet reproduction)
One-stop reference
Company Intelligence
Every listed company in Latin America — financials, ownership and structure for 1,450+ companies across 26 exchanges, in one place.
Browse the directory →
RT
Ask Rio Times
17 years of Latin America reporting, on demand.
Open the full Ask Rio Times →

The study, conducted with 100 subjects, shows that all had T-cell responses against a range of coronavirus proteins, including the spike protein used as a marker in many vaccine studies, after half a year. Those with symptoms showed levels at least 50 percent higher than those with no symptoms.

As some vaccines near the finish line in the race for an immunizer, it is still unclear how long the protection offered would last. A low number of patients fell ill with Covid-19 twice.

“This is promising news,” said Fiona Watt, executive chairperson of the UK Medical Research Council. “If natural infection with the virus can trigger a robust T-cell response, then it could mean that a vaccine could do the same.”

An earlier study, published last month by Imperial College London, raised concerns that immunological defenses might decrease, as it showed that the percentage of Britons with antibodies decreased over time.

T-cells are not antibodies. They are white blood cells that can recall past diseases, kill virus-infected cells and awaken antibodies to command defenses when required. People infected with another coronavirus responsible for the SARS epidemic in 2003, for instance, still show a T-cell response to the disease 17 years later.

The study, conducted by a group of immunologists from 17 universities named Coronavirus Immunology Consortium in the United Kingdom, has not yet been peer reviewed. It may be the first to show that a robust immunological memory against the virus persists for this length of time, the authors said.

None of the patients whose blood and serum samples were studied had been hospitalized with Covid-19.

Source: InfoMoney

This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error

Read More from The Rio Times

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map
All News Brazil art news Brazil Best English News Brazil Best News Brazil Brazil Brazil economy Brazil football Brazil Museum Fire Brazil national football team Brazil News Brazil Pension Reform Brazil Real Brazil Visa Brazilian Newspaper Business News Brazil Covid-19 Latin America culture news Brazil English Culture News Brazil English Info Brazil English Info Rio de Janeiro English News Argentina English News Belo Horizonte English News Bolivia English News Brasilia English News Brazil English News Chile English News Colombia English News Cuba English News Curitiba English News Ecuador English News El Salvador English News Falklands English News Florianopolis English News Guetamala English News Latin America English News Mexico English News Panama English News Paraguay English News Peru English News Rio de Janeiro English News Sao Paulo English News Uruguay English News Venezuela English Newspaper Brazil English Newspaper Rio de Janeiro Falkland Islands General News Brazil Info Brazil Info Rio de Janeiro Invest in Brazil Mining News Brazil Natioal Museum of Brazil News Argentina News Bolivia News Brasilia news Brazil News Chile News Colombia News Cuba News Ecuador News El Salvador News Falklands News Florianopolis News Guatemala News Latin America News Mexico News Panama News Paraguay News Peru News Rio de Janeiro News Uruguay News Venezuela Oil News Brazil President of Brazil Rio de Janeiro São Paulo News Science News Brazil travel Brazil Travel News Brazil Universities Brazil

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.